whitepaper
Whitepaper: Identification of specific PD-L1 Affimer inhibitors with therapeutic potential
Affimer® proteins are unique affinity proteins that exhibit high affinity and high specificity binding across a range of reaction conditions...
List view / Grid view
Therapeutics
article
Computational methods for drug repositioning
Bioinformatics and computational techniques are now experiencing increased attention as a means of improving the costly and time-consuming drug development process...
article
The frightening emergence of antibiotic-resistant bacteria
Bacterial resistance to antibiotics is on the rise and a return to the ‘pre-antibiotic’ era has become a frightening possibility. Various factors are responsible for this situation: the overuse of antibiotics in human medicine and animal husbandry, insufficient public funding for research into fundamental bacteriology including resistance mechanisms, and a…
article
Finding a cure for neglected tropical diseases with cell-based assays
Neglected tropical diseases pose a significant threat to public health and affect nearly one billion people in tropical and sub-tropical regions throughout the world. There is a pressing need to identify new therapeutics for NTDs and many developed nations are participating in drug discovery efforts...
article
Antibody fragment technology and avian IgY antibodies: a powerful combination
Recombinant monoclonal antibodies or antibody biologics have been successfully developed as diagnostic and therapeutic agents...
article
The challenges associated with ‘de-risking’ early-stage therapeutic targets
The pharmaceutical industry is searching for novel drug targets that could produce the next generation of ‘first-in-class’ therapeutic agents. The challenge for academia is to identify and translate such targets and to provide starting points and confidence in the underlying science. The aim should be to generate evidence that modulation…
article
Should LC-MS/MS proteomics guide targeted drug selection for cancer patients?
History has demonstrated that the use of companion in vitro diagnostic tests to select cancer patients positive for a drug target significantly improves response to targeted anti-cancer therapies...
news
Key paper on proteomics in the field of allergy published in the World Allergy Journal
10 August 2015 | By Charlotte Batchelor, Drug Target Review
Allergy Therapeutics has announced the publication of a key paper and featured article in the World Allergy Journal about proteomics in the field of allergy...
article
Targeting cancer metabolism
Cancer cells are addicted to glucose and glutamine, which enables them to generate the energy and macromolecule synthesis intermediates to support their growth...
article
The importance of adequately triaging hits from HTS campaigns
High throughput screening (HTS) continues to be employed in drug discovery as the primary source of identifying chemical starting points for drug discovery and tool compounds for chemical biology, respectively. Although small molecule drug discovery efforts have focused largely upon enzyme, receptor and ion-channel targets, there has been an increase…
article
Investigation of venom use in stem cell differentiation
Stem cells differentiate to form more than 200 specialised cells, including erythroid bodies, haematopoietic cells, myogenic cells, neural cells, signalling cells and structural cells, such as hepatocytes. Differentiation of stem cells triggers a number of variable changes in the cell, such as membrane potential, responsiveness to signal, metabolic activities, and…
article
From hype to hope: challenging the norm in lead discovery
From the beginning of time in the drug discovery world, the integration of disciplines has driven the identification of new lead molecules. Chemists, pharmacologists and biologists work together to understand a disease state and how to perturb that state back towards a normal healthy condition. However, in the early days…
news
Pfizer announces key appointments in BioTherapeutics R&D and Rinat
7 May 2015 | By Victoria White
Pfizer has made two strategic appointments in the leadership of their BioTherapeutics Research and Development and Rinat units...
article
Immune checkpoint inhibitors: targets on the horizon
Immune checkpoint inhibitory antibodies have provided a great conceptual change in the field of immune-oncology. Rather than targeting the tumour directly, these novel drugs are aimed at preventing the interactions between the tumour and the immune system, which the cancer exploits to evade immune recognition...
news
Medivir and CRT collaborate to develop new class of cancer drugs
13 April 2015 | By Victoria White
Medivir and CRT have announced a partnership to develop a new class of drugs that has shown promise for treating a range of different cancers...
